2020
DOI: 10.1101/2020.04.17.046516
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Murine cytomegaloviruses m139 targets DDX3 to curtail interferon production and promote viral replication

Abstract: 1Cytomegaloviruses (CMV) infect many different cell types and tissues in their respective hosts. 2 Monocytes and macrophages play an important role in CMV dissemination from the site of UBR5, m139 ensures efficient viral replication in endothelial cells. Importantly, we identify 33 m139 as a new viral DDX3 inhibitor, which curtails the production of interferon in 34 macrophages. 35 36 157 to nuclear replication compartments (Figures S1). These finding suggested that the viral m139 158 and E1 proteins interact … Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
2
2

Relationship

2
2

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 66 publications
(91 reference statements)
0
1
0
Order By: Relevance
“…CRISPR/Cas9 gene editing was used to generate Sel1L knockout MEFs essentially as described (20,42). Briefly, two different guide RNAs (5'-GTCGTTGCTGCTGCTCTGCG-3' and 5'-GCTGCTCTGCGCGGTGCTCC-3') targeting the murine Sel1L gene were designed using E-CRISP (http://www.e-crisp.org/E-CRISP/designcrispr.html) and inserted into the lentiviral vector pSicoR-CRISPR-puroR (kindly provided by R. J. Lebbink, University Medical Center Utrecht, Netherlands).…”
Section: Crispr/cas9 Gene Editingmentioning
confidence: 99%
“…CRISPR/Cas9 gene editing was used to generate Sel1L knockout MEFs essentially as described (20,42). Briefly, two different guide RNAs (5'-GTCGTTGCTGCTGCTCTGCG-3' and 5'-GCTGCTCTGCGCGGTGCTCC-3') targeting the murine Sel1L gene were designed using E-CRISP (http://www.e-crisp.org/E-CRISP/designcrispr.html) and inserted into the lentiviral vector pSicoR-CRISPR-puroR (kindly provided by R. J. Lebbink, University Medical Center Utrecht, Netherlands).…”
Section: Crispr/cas9 Gene Editingmentioning
confidence: 99%